Molecular targeting the translational control axis in Wnt/beta-catenin signaling pathway

Wnt/β-catenin 信号通路中翻译控制轴的分子靶向

基本信息

  • 批准号:
    10456829
  • 负责人:
  • 金额:
    $ 34.49万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-08-01 至 2024-07-31
  • 项目状态:
    已结题

项目摘要

Gene expression is regulated mainly at both transcriptional and translational levels. Compared with transcriptional regulation, translational control is under-studied and the roles of eukaryotic initiation factors (eIFs) in regulating gene expression, in signal transduction, and in regulating cell growth have not been appreciated to the level of their importance. The prevailing theory of translational control in gene expression is that the expression level of eIFs directly relates to the rate of translation initiation and level of protein synthesis. According to this theory, the increased expression of eIFs such as eIF4E, a putative subunit of eIF4F complex, would increase translation initiation rate and protein synthesis. However, we recently found that over- expression of eIF3a, a putative subunit of eIF3 complex, inhibited synthesis of tumor suppressor proteins and caused malignant transformation of intestinal epithelial cells. We also found that eIF3a expression was up-regulated in colon cancers and adenoma polyps possibly due to APC mutation and activation of β-catenin signaling. We hypothesize that eIF3a may serve as a turning point in the canonical Wnt/β-catenin signaling pathway and add an additional translational control axis to this pathway in colon tumorigenesis/familial adenomatous polyposis and that the elevated eIF3a expression due to β-catenin activation generates free unbound eIF3a that may gain a non-canonical activity in inhibiting synthesis of tumor suppressor proteins by binding to their mRNAs. The long-term goal of this project is to understand the mechanisms of translational control in gene expression, signal transduction, and in aberrant proliferation of intestinal/colon epithelial cells. Specifically, we will investigate the non-canonical function of eIF3a in Wnt/β-catenin signal transduction and in colon tumorigenesis and FAP with an ultimate goal to establish eIF3a as a potential target for drug discovery. To this end, we plan to accomplish the following specific aims to determine (1) the mechanism of eIF3a action in translational regulation and in colon tumorigenesis; (2) the mechanism of translational regulation in tumor suppressor expression, and (3) the mechanism of transcriptional regulation of eIF3a expression and to establish eIF3a as potential target. The information and probes obtained from this study will help us understand the molecular mechanisms of translational control axis in Wnt/β- catenin signaling pathway, the role of eIF3a in translational regulation of tumor suppressor mRNAs, and to establish eIF3a as a potential target for cancer treatemnts.
基因表达主要在转录和翻译水平上调节。 与转录调控相比,翻译调控研究较少, 真核起始因子(eIFs)在调节基因表达、信号转导和免疫调节中的作用 调节细胞生长尚未被认识到其重要性的水平。现行 基因表达中的翻译控制理论认为eIFs的表达水平直接影响基因的表达, 与翻译起始速率和蛋白质合成水平有关。根据这一理论, eIFs如eIF 4 E(eIF 4F复合物的假定亚基)的表达增加, 增加翻译起始速率和蛋白质合成。然而,我们最近发现,过度- eIF 3a是eIF 3复合物的一个亚基,其表达可抑制肿瘤抑制因子的合成。 蛋白质并导致肠上皮细胞恶性转化。我们还发现 eIF 3a在结肠癌和腺瘤息肉中表达上调,可能是APC所致 β-catenin信号的突变和激活。我们假设eIF 3a可能作为一种 在经典的Wnt/β-catenin信号通路的转折点,并添加一个额外的 结肠肿瘤发生/家族性腺瘤性息肉病中该途径的翻译控制轴 并且由于β-连环蛋白激活引起的eIF 3a表达升高产生了游离的未结合的 eIF 3a可能在抑制肿瘤抑制蛋白的合成中获得非典型活性 通过与它们的mRNA结合。本项目的长期目标是了解 在基因表达,信号转导和细胞异常增殖中的翻译控制 肠/结肠上皮细胞。具体来说,我们将研究的非典型功能, eIF 3a在Wnt/β-catenin信号转导和结肠肿瘤发生和FAP中的作用 目标是将eIF 3a作为药物发现的潜在靶点。为此,我们计划 实现以下具体目标,以确定(1)eIF 3a在 翻译调控与结肠肿瘤发生的关系;(2)结肠肿瘤发生中的翻译调控机制。 肿瘤抑制基因的表达;(3)eIF 3a的转录调控机制 表达,并建立eIF 3a作为潜在的目标。信息和探测器从 本研究将有助于我们了解Wnt/β- 连环蛋白信号通路,eIF 3a在肿瘤抑制基因翻译调控中的作用, 并建立eIF 3a作为癌症治疗的潜在靶点。

项目成果

期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Translation initiation factor eIF3a regulates glucose metabolism and cell proliferation via promoting small GTPase Rheb synthesis and AMPK activation.
  • DOI:
    10.1016/j.jbc.2022.102044
  • 发表时间:
    2022-07
  • 期刊:
  • 影响因子:
    4.8
  • 作者:
    Ma, Shijie;Dong, Zizheng;Huang, Yanfei;Liu, Jing-Yuan;Zhang, Jian-Ting
  • 通讯作者:
    Zhang, Jian-Ting
eIF3a regulation of mTOR signaling and translational control via HuR in cellular response to DNA damage.
  • DOI:
    10.1038/s41388-022-02262-5
  • 发表时间:
    2022-04
  • 期刊:
  • 影响因子:
    8
  • 作者:
    Ma, Shijie;Dong, Zizheng;Huang, Yanfei;Liu, Jing-Yuan;Zhang, Jian-Ting
  • 通讯作者:
    Zhang, Jian-Ting
eIF3d: A driver of noncanonical cap-dependent translation of specific mRNAs and a trigger of biological/pathological processes.
  • DOI:
    10.1016/j.jbc.2023.104658
  • 发表时间:
    2023-05
  • 期刊:
  • 影响因子:
    4.8
  • 作者:
    Ma, Shijie;Liu, Jing-Yuan;Zhang, Jian-Ting
  • 通讯作者:
    Zhang, Jian-Ting
Novel synthetic bisindolylmaleimide alkaloids inhibit STAT3 activation by binding to the SH2 domain and suppress breast xenograft tumor growth.
  • DOI:
    10.1038/s41388-017-0076-0
  • 发表时间:
    2018-05
  • 期刊:
  • 影响因子:
    8
  • 作者:
    Li X;Ma H;Li L;Chen Y;Sun X;Dong Z;Liu JY;Zhu W;Zhang JT
  • 通讯作者:
    Zhang JT
Translational regulation of Chk1 expression by eIF3a via interaction with the RNA-binding protein HuR.
  • DOI:
    10.1042/bcj20200025
  • 发表时间:
    2020-05-29
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Dong Z;Liu J;Zhang JT
  • 通讯作者:
    Zhang JT
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jian-Ting Zhang其他文献

Jian-Ting Zhang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jian-Ting Zhang', 18)}}的其他基金

Targeting FASN to eliminate metastatic breast cancer in the brain
靶向 FASN 消除脑部转移性乳腺癌
  • 批准号:
    10721671
  • 财政年份:
    2023
  • 资助金额:
    $ 34.49万
  • 项目类别:
Molecular targeting the translational control axis in Wnt/beta-catenin signaling pathway
Wnt/β-catenin 信号通路中翻译控制轴的分子靶向
  • 批准号:
    10225293
  • 财政年份:
    2017
  • 资助金额:
    $ 34.49万
  • 项目类别:
Molecular targeting the translational control axis in Wnt/β-catenin signaling pathway
分子靶向 Wnt/β-连环蛋白信号通路中的翻译控制轴
  • 批准号:
    9389545
  • 财政年份:
    2017
  • 资助金额:
    $ 34.49万
  • 项目类别:
Molecular targeting the translational control axis in Wnt/beta-catenin signaling pathway
Wnt/β-catenin 信号通路中翻译控制轴的分子靶向
  • 批准号:
    9747809
  • 财政年份:
    2017
  • 资助金额:
    $ 34.49万
  • 项目类别:
Therapeutic targeting of stratifin structure and function
Stratifin 结构和功能的治疗靶向
  • 批准号:
    8457985
  • 财政年份:
    2010
  • 资助金额:
    $ 34.49万
  • 项目类别:
Therapeutic targeting of stratifin structure and function
Stratifin 结构和功能的治疗靶向
  • 批准号:
    8256539
  • 财政年份:
    2010
  • 资助金额:
    $ 34.49万
  • 项目类别:
Therapeutic targeting of stratifin structure and function
Stratifin 结构和功能的治疗靶向
  • 批准号:
    8102695
  • 财政年份:
    2010
  • 资助金额:
    $ 34.49万
  • 项目类别:
Therapeutic targeting of stratifin structure and function
Stratifin 结构和功能的治疗靶向
  • 批准号:
    8676460
  • 财政年份:
    2010
  • 资助金额:
    $ 34.49万
  • 项目类别:
Therapeutic targeting of stratifin structure and function
Stratifin 结构和功能的治疗靶向
  • 批准号:
    7986480
  • 财政年份:
    2010
  • 资助金额:
    $ 34.49万
  • 项目类别:
Targeting the amino terminal gate of human MRP1
靶向人类 MRP1 的氨基末端门
  • 批准号:
    7628677
  • 财政年份:
    2007
  • 资助金额:
    $ 34.49万
  • 项目类别:

相似海外基金

APC mutation and breast cancer: Prevention by curcumin
APC 突变与乳腺癌:姜黄素预防
  • 批准号:
    7425971
  • 财政年份:
    2006
  • 资助金额:
    $ 34.49万
  • 项目类别:
APC mutation and breast cancer: Prevention by curcumin
APC 突变与乳腺癌:姜黄素预防
  • 批准号:
    7620114
  • 财政年份:
    2006
  • 资助金额:
    $ 34.49万
  • 项目类别:
APC mutation and breast cancer: Prevention by curcumin
APC 突变与乳腺癌:姜黄素预防
  • 批准号:
    7247167
  • 财政年份:
    2006
  • 资助金额:
    $ 34.49万
  • 项目类别:
APC mutation and breast cancer: Prevention by curcumin
APC 突变与乳腺癌:姜黄素预防
  • 批准号:
    7132974
  • 财政年份:
    2006
  • 资助金额:
    $ 34.49万
  • 项目类别:
APC mutation and breast cancer: Prevention by curcumin
APC 突变与乳腺癌:姜黄素预防
  • 批准号:
    8260721
  • 财政年份:
    2006
  • 资助金额:
    $ 34.49万
  • 项目类别:
APC mutation and breast cancer: Prevention by curcumin
APC 突变与乳腺癌:姜黄素预防
  • 批准号:
    7813928
  • 财政年份:
    2006
  • 资助金额:
    $ 34.49万
  • 项目类别:
APC mutation and the initiation of colorectal cancer
APC突变与结直肠癌的发生
  • 批准号:
    nhmrc : 400251
  • 财政年份:
    2006
  • 资助金额:
    $ 34.49万
  • 项目类别:
    NHMRC Project Grants
Development of novel screening method by detection of APC mutation from colorectal cancer cells in stool
开发粪便中结直肠癌细胞APC突变检测新筛查方法
  • 批准号:
    17591404
  • 财政年份:
    2005
  • 资助金额:
    $ 34.49万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
DIETARY INTERACTIONS WITH APC MUTATION IN COLON CANCER
饮食与结肠癌 APC 突变的相互作用
  • 批准号:
    2748805
  • 财政年份:
    1995
  • 资助金额:
    $ 34.49万
  • 项目类别:
DIETARY INTERACTIONS WITH APC MUTATION IN COLON CANCER
饮食与结肠癌 APC 突变的相互作用
  • 批准号:
    2111759
  • 财政年份:
    1995
  • 资助金额:
    $ 34.49万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了